What does the changing drug discovery landscape mean for the future?

This is the latest episode of the free narrated DDW podcast, “What does the changing drug discovery and development landscape mean for the future?”. It covers three articles written for Volume 22, Issue 4 – Fall 2021 of DDW, narrated by DDW Multimedia Editor Megan Thomas. They are called “The potential of small molecules and biologics for new therapeutics”, “AE reporting turnarounds and the translation issue” and “Why we are on the cusp of a golden age of medicine”.

Dr Seth Lederman is a physician-scientist, entrepreneur, and CEO of Tonix Pharmaceuticals. In the first article, he talks to Lu Rahman about Tonix Pharmaceuticals’ mission to research and manufacture small molecules and biologics for the treatment of CNS and immunological conditions.

In the second article, Kathleen O’Brien of Amplexor Life Sciences lays out a blueprint for centralising global AE reporting.

In the third article, Panna Sharma, the President and CEO of Lantern Pharma, a clinical-stage oncology biotech using AI and genomics to innovate the rescue, revitalisation, and development of precision cancer therapeutics, spoke to Lu Rahman about this biotech and explains why he believes AI is about to change the drug development landscape.

You can listen below, or find The Drug Discovery World Podcast on SpotifyGoogle Play and Apple Podcasts.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free